LensGen secures $21 million in financing for Juvene IOL

LensGen has closed $21 million in Series A financing for Juvene, its modular fluid-optic accommodating IOL, the company announced in a press release.

Led by Hoya Group’s corporate investment arm and including funding from Relativity Healthcare partners, the financing includes an option to expand the commitment by $5 million, the release said.

The Juvene IOL is designed to restore clear, continuous vision at all distances for patients with cataracts and presbyopia, according to the release.

“We are pleased to attract an experienced ophthalmology and corporate strategic investor like Hoya to accelerate our efforts to further develop and bring to market this innovative and elegant lens solution for treating presbyopia,” Ramgopal Rao, LensGen’s CEO and founder, said in the release.

LensGen has closed $21 million in Series A financing for Juvene, its modular fluid-optic accommodating IOL, the company announced in a press release.

Led by Hoya Group’s corporate investment arm and including funding from Relativity Healthcare partners, the financing includes an option to expand the commitment by $5 million, the release said.

The Juvene IOL is designed to restore clear, continuous vision at all distances for patients with cataracts and presbyopia, according to the release.

“We are pleased to attract an experienced ophthalmology and corporate strategic investor like Hoya to accelerate our efforts to further develop and bring to market this innovative and elegant lens solution for treating presbyopia,” Ramgopal Rao, LensGen’s CEO and founder, said in the release.